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Liver enzymes alanine aminotransferase (ALT) and gamma glutamyl transferase (GGT) are markers for type 2 diabetes mellitus
(T2DM); alkaline phosphatase is a marker of liver disease. Mexican-American adolescents are disproportionately aﬀected by
T2DM, while in Mexico its prevalence is emerging. We assessed liver biomarkers and lipid proﬁles among Mexican and
Mexican-American adolescents 10–14 years old with high/low risk of T2DM through a cross-sectional, descriptive study (Texas
n = 144; Mexico n = 149). We included family medical histories, anthropometry, and blood pressure. Obesity was present in
one-third of subjects in both sites. ALT (UL) was higher (p < 0 001) in high-risk adolescents (23.5 ± 19.5 versus 17.2 ± 13.4 for
males, 19.7 ± 11.6 versus 15.1 ± 5.5 for females), in Toluca and in Texas (26.0 ± 14.7 versus 20.0 ± 13.2 for males, 18.2 ± 13.4
versus 14.6 ± 10.1 for females), as well as GGT (UL) (p < 0 001) (18.7 ± 11.1 versus 12.4 ± 2.3 for males, 13.6 ± 5.8 versus 11.5
± 3.9 for Mexican females; 21.0 ± 6.8 versus 15.4 ± 5.5 for males, 14.3 ± 5.0 versus 13.8 ± 5.3 for females in Texas). We found no
diﬀerences by sex or BMI. Total cholesterol and HDL were higher among Mexican-Americans (p < 0 001). In conclusion,
multiple risk factors were present in the sample. We found diﬀerences by gender and between high and low risk for T2DM
adolescents in all liver enzymes in both sites.
1. Introduction
Type 2 diabetes mellitus (T2DM) is a chronic condition that
results from a progressive insulin secretory defect related to
insulin resistance caused by a combination of genetic and
lifestyle factors [1, 2]. While most important lifestyle factors
include unhealthy nutrition and physical inactivity that
promote overweight and abdominal obesity [1, 3], genetic
factors may vary across populations. It is well established
that Mexicans have a high genetic predisposition for
T2DM [4, 5]; although genes that predispose an individ-
ual to T2DM are considered an essential factor in the
development of the disease, activation of a genetic predis-
position requires the presence of environmental and
behavioural factors, particularly those associated with life-
styles [6].
The increasing worldwide prevalence of overweight,
obesity, and metabolic syndrome has revealed that liver
enzymes have a potential role as determinants of T2DM
and other metabolic conditions such as cardiovascular
Hindawi
Journal of Diabetes Research
Volume 2017, Article ID 4262536, 9 pages
https://doi.org/10.1155/2017/4262536
disease, hyperlipidaemia, and atherothrombotic risk pro-
ﬁle [7–9]. Measurement of liver enzymes has become
accessible and widely used not only in detecting the inci-
dence, development, and prognosis of liver disease with
obvious clinical symptoms but also in assessing overall
health status and liver metabolic status [7, 10]. Gamma
glutamyl transferase (GGT) is predictive of future diabe-
tes [11–14]. Alanine aminotransferase (ALT) increases
with insulin resistance, an independent predictor of
T2DM [15, 16]. ALT is the most speciﬁc marker of this
hepatic pathology [17]. Even within the normal range,
both ALT and GGT enzymes have been reported to pre-
dict incident diabetes, independent of BMI and alcohol
intake [11, 17–19]. However, while some studies have
demonstrated a stronger association between GGT and
diabetes than between ALT and diabetes [14, 20], others
have reported the opposite [21]. A third enzyme, alkaline
phosphatase (ALP), is not speciﬁc of T2DM but is a
marker of liver disease, particularly nonalcoholic fatty liver
disease (NAFLD) which is associated with insulin resis-
tance [22, 23]. Reference intervals for all three of them
are age and sex related.
Dyslipidaemia occurs in two-thirds of diabetic cases and
is mainly characterized by hypertriacylglyceridaemia, low
HDL cholesterol, and increased low-density lipoprotein con-
centrations [24]. There is an association of hyperinsulinemia
with hypertriacylglyceridaemia, low HDL, and high LDL
[14]. Dyslipidaemia is highly prevalent among Mexicans,
and the prevalence of insulin resistance associated with
hypertriacylglyceridaemia in the Mexican population, from
various studies, ranges from 36.4% to 59% [25].
In Mexico, according to the most recent National
Health and Nutrition Survey 2012 (ENSANUT 2012),
there are 6.5 million people with diabetes (9.2%), with a
rise of nearly 25 percent from 2006 to 2012 [26]. There
is an increase in the prevalence of T2DM among Mexican
adolescents, and among Mexican-American adolescents liv-
ing in the US, the increase is even higher [27] (i.e., nearly
1% versus 28%, resp.) [26, 28]. The prevalence of T2DM is
disproportionally high among Mexican-Americans com-
pared with other Hispanic groups (5% for Puerto Ricans,
3% for Central Americans, 2% for South Americans, and
1% for Cubans) or with non-Hispanic white Americans
[29]. When compared by age group, the prevalence of
T2DM among 15- to 19-year-olds is twice the prevalence
among 10- to 14-year-olds. In Mexico, the State of Mexico
is the second state with the highest prevalence of T2DM in
males and the tenth state in females [30]. Toluca is the capital
of the State of Mexico.
To our knowledge, no previous study has described
serum concentrations of liver enzymes in adolescents at
risk for T2DM. As risk factors for T2DM are high
among Mexicans and Mexican-Americans, we aimed to
assess and compare liver biomarkers and lipid proﬁles
among Mexican and Mexican-American adolescents 10–
14 years of age, who are at risk of developing T2DM.
We hypothesized that biomarkers and lipid proﬁles would
be higher among Mexican-American adolescents as a bio-
logical indicator of their higher prevalence of T2DM.
2. Materials and Methods
2.1. Study Design and Sample. A cross-sectional study of
factors associated with a high risk for T2DM in adolescents
10–14 years of age was designed in collaboration with the
University of North Texas Health Science Center (UNTHSC)
in Fort Worth and the Center for Research and Graduate
Studies in Health Sciences at the Universidad Autónoma
del Estado de México (UAEM) in Toluca. The sample
included 300 couples of healthy adolescents and their
father/mother/guardian, equally distributed between Toluca
and Texas. In each site, low- and high-risk adolescents were
included (see Participants). We used a probabilistic sample
with an alpha of 5%, an expected conﬁdence interval of
95%, and a percentage for completion of 66%. Subjects with
chronic diseases such as cystic ﬁbrosis, genetic syndromes,
hypo- or hyperthyroidism, and adrenal disease; those who
self-reported use of corticosteroids during the previous year
of the study, and had a fasting ﬁnger-prick gluco-
se≥ 126mg/dl or postprandial≥ 200mg/dl, which are indica-
tive of diabetes mellitus [31], were excluded.
2.2. Participants.We drew our sample from fourth- to ninth-
grade students. In Toluca, students enrolled in two public
middle schools were invited to participate. In Texas, partici-
pants were recruited actively and passively, from paediatrics
and family medicine clinics of the North Texas Primary Care
Practice-Based Research Network (NorTex) and through
community events.
Participants were classiﬁed according to their risk status
using a noninvasive method, as “high risk” if three or more
of the following risk factors for T2DM were present or “low
risk” if two or less risk factors for T2DM were present [32]:
(1) Family history of T2DM in ﬁrst and second-degree
family members
(2) Signs of insulin resistance (i.e., presence of acanthosis
nigricans)
(3) BMI-for-age sex-speciﬁc≥ 95 percentile
(4) Family history of hypertension or systolic blood
pressure/diastolic blood pressure≥ 95 percentile
(5) Fasting ﬁnger prick glucose 100–125mg/dl (5.6–
6.9mmol/l) [31].
2.3. Data Collection. Participants were assigned two appoint-
ments in Toluca. During the ﬁrst appointment, there was a
direct interview with the parent (father/mother/guardian)
and the adolescent. Each one responded to their correspond-
ing demographic questionnaires, and a screening for ﬁnger-
prick fasting glucose levels to assess overall risk for diabetes
was done to conﬁrm inclusion to the study. Ethnic back-
ground was classiﬁed depending on parental origin and
child’s place of birth in both places. During the second
appointment, clinical and anthropometric measurements
and blood samples were obtained. In Texas, participants were
assigned only one appointment to complete all information.
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Clinical measurements included blood pressure and the
physical examination of the neck to determine the absence/
presence of acanthosis nigricans. After previous standardiza-
tion, blood pressure was measured in the dominant arm
using the auscultation method and a mercury sphygmoma-
nometer. Hypertension was deﬁned as average systolic blood
pressure (SBP) and/or diastolic blood pressure (DBP) greater
than or equal to the 95th percentile for sex, age, and height
[33]. For the analysis, we used the mean of two systolic/dia-
stolic values taken ﬁve minutes apart by the same examiner.
Anthropometric measurements included height, weight,
waist, and hip circumferences [34]. We used standard
methods by trained personnel. We recorded height by using
a portable stadiometer and weight with an electronic scale.
We calculated body mass index (BMI-for-age) as weight
in kilograms divided by height in squared meters (kg/
m2). Overweight was deﬁned as a BMI between the 85th
and 95th percentile and CDC Standards [35] deﬁned as
a BMI equal or above the 95th percentile obesity. We
determined central adiposity by measuring waist circum-
ference. Waist circumference risk was deﬁned between
the 85th and 90th CDC percentiles for adolescents with
the same age and sex [36].
Blood samples were collected to measure lipid proﬁles
and nonfractionated liver enzymes: alkaline phosphatase
(ALP), gamma glutamyl transpeptidase (GGT), and alanine
aminotransferase (ALT). In Toluca, trained personnel from
UAEM obtained blood samples at the school. At UNTHSC,
trained personnel obtained blood samples from Quest
Diagnostics at the Patient Care Centre. Quest Diagnostics
performed all laboratory tests at both sites and we used Quest
normative data for adolescents of similar age and sex. All
information (questionnaires, blood samples, clinical mea-
surements, and laboratory analyses) were associated with a
unique identiﬁcation number. Only 7% of liver biomarkers
and lipids data was missing.
2.4. Statistical Analysis. Statistical analyses were performed
using the SPSS software 19.0 (Chicago, IL). Data are presented
as means and standard deviations (SD) or number and valid
percentage for central and spread measurements. t-tests and
χ2 tests were used to evaluate diﬀerences in adolescents’
anthropometric and clinical measurements and biomarkers
and lipid proﬁles. Adolescents were stratiﬁed by risk status,
sex, and location (Toluca versus Texas) to examine diﬀerences
betweenMexican andMexican-Americans. Since the propor-
tion of male versus female were diﬀerent, we compared male
versus male and female versus female, allowing for increased
internal validity of the study. This may have accounted for
the diﬀerences in bodyweight, waist circumference, hyperten-
sion, and other possible confounders.
We used three-way ANOVA for testing diﬀerences of
biological markers and lipid proﬁles between groups. We also
used analysis of covariance to control for BMI and sex as
possible confounders between study groups. Statistical signif-
icance was accepted at the 0.05 level.
2.5. Ethics Approval. The Committee for Ethics and Research
at Universidad Autónoma del Estado de México in UAEM,
the Institutional Review Board at UNTHSC, and the Toluca
school district board of directors approved the protocol.
Once informed, a written consent was obtained from both
parents or a guardian and assent from the adolescent during
an informative meeting with parents and adolescents. All
subjects accepted to participate.
3. Results
A total of 149 adolescents in Toluca and 144 adolescents in
Texas completed the study. All reported conﬁrmed ethnicity.
We used reminder telephone calls in Texas and attempts
to reschedule missed appointments in schools in Toluca.
Missing values generally resulted from inability to obtain
blood samples. No adolescent withdrew from the study.
Mean age was similar between Mexican and Mexican-
American adolescents (12.02± 1.20 years and 11.97± 1.52
years for females; 11.83± 1.23 years and 11.96± 1.37 years
for males, resp.). There was a signiﬁcantly higher proportion
of Mexican adolescent females compared with males (61.1%
in Toluca and 38.9% in Texas; p = 0 032, data not shown).
Most females in Toluca were attending middle school
while most females in Texas were attending elementary
school (p < 0 001) (Table 1). The highest prevalence of ado-
lescents classiﬁed with high-risk status, both males and
females, was found at 12 years of age among the Mexican-
Americans and at 14 years of age among the Mexicans (data
not shown).
3.1. Characteristics of Participants. We found no diﬀerences
in weight and height in Mexicans adolescents, while height
was signiﬁcantly higher in Texas males compared with
females (p < 0 001). BMI z-score distributionwas signiﬁcantly
diﬀerent in both sites within and between groups (p < 0 001,
data not shown) (Table 1). In Toluca, waist circumference
and percentage body fat were signiﬁcantly higher (p < 0 05)
among adolescent females (75.01± 10.80 and 25.52± 11.74,
resp.) compared with adolescent males (71.60± 9.49 and
20.93± 12.18, resp.). In Texas, percentage of body fat was
signiﬁcantly higher in adolescent females compared with
adolescent males (31.41± 8.99 versus 27.03± 10.85, resp.).
Prevalence of obesity was higher than prevalence of over-
weight in both females and males. In Toluca, obesity was
present in 49.45% and 34.48% adolescent females and males.
In Texas, obesity was present in 35.71% and 45.94% adoles-
cent females andmales. Diastolic blood pressure was diﬀerent
between females and males in Toluca (p < 0 001), while sys-
tolic blood pressure was diﬀerent between females and males
in Texas (p < 0 05).
3.2. Risk Factors for T2DM. We assessed ﬁve risk factors for
T2DM. In Toluca, only the prevalence of known family
history of hypertension was diﬀerent between adolescent
females and adolescent males being higher for males
(51.7% versus 31.8%, resp.; p < 0 05) (Table 2). In Texas,
prevalence of known family history of diabetes and
presence of acanthosis nigricans were signiﬁcantly higher
in adolescent females (82.8% and 55.7%, resp.) than in ado-
lescent males (63.5% and 40.5%, resp.) (p < 0 05). Fasting
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Table 1: Characteristics of the 10- to 14-year-old Mexican and Mexican-American adolescents by sex and location.
Characteristics
Adolescents
Toluca (n = 149) Texas (n = 144)
Females
(n = 91)
Males
(n = 58) p
∗ Females
(n = 70)
Males
(n = 74) p
∗
Age, years 12.02± 1.20 11.83± 1.23 0.431 11.97± 1.52 11.96± 1.37 0.590
Education
Elementary school (%) 46.1 58.6
0.000
51.4 48.6
0.047
Middle school (%) 53.8 41.3 48.5 51.3
Weight (kg) 52.35± 13.68 49.72± 14.17 0.263 54.31± 15.88 59.90± 21.21 0.077
Height (m) 149.71± 6.51 148.27± 8.83 0.256 150.17± 7.00 155.61± 11.76 0.001
BMI (kg/m2) 23.17± 5.26 22.24± 5.01 0.283 23.86± 6.01 24.08± 5.83 0.824
BMI-for-age z-score 0.88± 1.16 0.92± 1.38 0.120 1.08± 1.20 1.24± 0.98 0.038
BMI-for-age z-score distribution1
Normal weight −0.16± 0.91 −0.17± 1.50 0.000 −0.13± 1.09 −0.05± 0.55 0.000
Overweight 1.24± 0.74 1.34± 0.36 0.000 1.37± 0.55 1.31± 0.22 0.000
Obese 1.76± 0.39 1.93± 0.45 0.000 2.05± 0.19 2.04± 0.42 0.000
Waist circumference (cm) 75.01± 10.80 71.60± 9.49 0.051 78.61± 12.66 82.57± 15.63 0.099
% body fat 25.52± 11.74 20.93± 12.18 0.022 31.41± 8.99 27.03± 10.85 0.010
Systolic blood pressure (mmHg) 115.24± 12.98 106.26± 9.54 0.251 107.53± 10.01 114.22± 22.05 0.037
Diastolic blood pressure (mmHg) 70.22± 11.18 63.67± 10.61 0.000 64.52± 5.63 65.23± 5.93 0.351
Blood pressure classiﬁcation2 0.297 0.824
Normal tension, % (n) 82.4 (75) 58.6 (34) 81.4 (57) 49.4 (37)
Prehypertension, % (n) 6.7 (6) 17.2 (10) 7.1 (5) 12.0 (9)
Stage 1 Hypertension, % (n) 6.7 (6) 15.5 (9) 8.5 (6) 26.3 (19)
Stage 2 Hypertension, % (n) 4.0 (4) 8.6 (5) 2.8 (2) 12.0 (9)
Age at menarche (females only) 11.38± 0.88 — — 11.02± 1.03 — —
Data are presented as mean ± standard deviation value unless otherwise speciﬁed. 1Normal weight between the 95th and 85th percentile; overweight between
the 85th and 95th percentile; obesity > 95th percentile. 2Normal tension < 90th percentile; prehypertension between the 90th and 94th percentile; stage 1
hypertension < 95th percentile; stage 2 hypertension < 99th percentile. ∗p value from overall test of association between Mexicans and Mexican-American
adolescents’ characteristics (χ2 test for categorical variables, Student’s t-test for continuous variables).
Table 2: Number of risk factors for T2DM present in 10- to 14-year-old Mexican and Mexican-American adolescents by sex and location.
Risk factors
Adolescents
Toluca (n = 149) Texas (n = 144)
Female
(n = 91)
Males
(n = 58) p
∗ Females
(n = 70)
Males
(n = 74) p
∗
Family history of diabetes (%) 61.5 (56) 56.9 (33) 0.347 82.8 (58) 63.5 (47) 0.007
Family history of hypertension (%) 31.8 (29) 51.7 (30) 0.021 1.4 (1) 2.7 (2) 0.262
BMI-for-age < 95th percentile (%) 42.8 (39) 31.0 (18) 0.134 31.4 (22) 35.1 (26) 0.234
Acanthosis nigricans, present (%) 37.4 (34) 32.7 (19) 0.347 55.7 (39) 40.5 (30) 0.049
Fasting glucose of 100–120mg/dl (%) 25.3 (23) 24.1 (14) 0.330 40.0 (28) 51.4 (38) 0.059
Number of T2DM risk factors present
0 16 7 0.041 6 13 0.056
1 23 22 0.270 25 23 0.467
2 13 7 0.024 18 16 0.194
3 25 13 0.037 16 17 0.691
4 13 7 0.025 5 4 0.091
5 1 2 0.368 0 1 0.211
∗p value from overall test of association between Mexicans and Mexican-American adolescents’ with χ2 test. Signiﬁcant values shown in bold.
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glucose was signiﬁcantly higher between adolescent females
and males in Texas compared with adolescent females and
males in Toluca (p < 0 05).
3.3. Biomarkers. Total cholesterol was signiﬁcantly diﬀerent
between females and males in Toluca and in Texas
(Table 3). No signiﬁcant diﬀerences were found in the
prevalence of normal/high biological marker concentra-
tions were observed within each site. Prevalence of high
values of high-density lipoproteins (HDL) was higher in
Toluca, both in adolescent females and males (72.9% ver-
sus 66.0%, resp.) (Table 3).
Signiﬁcant diﬀerences in ALP and GGT serum con-
centrations were found by site, by sex, and by risk status
(p < 0 001) (Table 4). Signiﬁcant diﬀerences in ALT serum
concentrations were found by sex (p < 0 05) and by risk
status (p < 0 001). Triacylglycerides were signiﬁcantly
higher in adolescents classiﬁed as high risk in both loca-
tions (p < 0 001). ALT was signiﬁcantly higher in high-
risk adolescent males (p < 0 001).
The ANOVA tests showed signiﬁcant diﬀerences for
ALP and GGT by sex and risk status together and for tria-
cylglycerides by location and risk status together (p < 0 05)
(Table 4). The analysis of covariance showed no diﬀer-
ences when controlling for sex and for BMI with the
exception of the concentrations of LDL which was signiﬁ-
cant by risk status when controlling for BMI (p = 0 009)
(data not shown).
4. Discussion
We aimed to compare two diﬀerent populations within same
age range, based on genetic, behavioural, and cultural simi-
larities. We found a high presence of multiple risk factors
for T2DM both in Toluca and in Texas, both in adolescent
females and adolescent males 10–14 years of age. This is con-
sistent with the high prevalence of T2DM in Mexican-
American adolescents (i.e., 10% total diabetes and 28% total
diabetes that is undiagnosed) [28] and the emerging preva-
lence of T2DM among Mexican adolescents (0.7% in 2012)
too [37]. Our results also showed that high-risk adolescents
in Toluca and in Texas (both adolescent females and males)
have signiﬁcantly higher serum concentrations of GGT com-
pared with low-risk adolescents in Toluca and in Texas (both
adolescent females and males). The presence of multiple risk
factors and the higher concentrations of liver enzymes may
contribute to the development of T2DM on many of these
adolescents classiﬁed with high-risk status later in life.
We expected to observe not only higher ALT and GGT
concentrations among high-risk adolescents, which we did,
but also higher concentrations among Mexican-American
adolescents in Texas according to the high prevalence of dia-
betes there. However, we did not ﬁnd the latter. An elevation
of ALT can be partly explained by higher BMI, waist circum-
ference, and triacylglycerides and lower HDL [9], which is
what the adolescents in Texas in our study showed. Another
smaller part can be explained by hepatitis infection, alcohol
Table 3: Mean± standard deviation of serum concentrations of biological markers in 10- to 14-year-old Mexican and Mexican-American
adolescents by location.
Biological markers
Normal1
Mean± SD (%)
Borderline2
Mean± SD (%)
High3
Mean± SD (%)
Toluca
Total cholesterol (mg/dl)∗
Triacilglycerides (mg/dl)
143.40± 16.03 (76.7)
89.28± 28.61 (76.1)
179.30± 7.05 (17.8)
164.64± 12.88 (7.4)
229.43± 24.19 (5.4)
278.79± 64.52 (16.4)
Cholesterol-HDL ratio 3.53± 0.64 (91.5) N/A 5.55± 0.73 (8.5)
High-density lipoprotein (HDL) (mg/dl)∗∗ 46.32± 11.27 (72.9) 41± 8.31 (8.5) 33.19± 5.12 (18.6)4
Low-density lipoprotein (LDL) (mg/dl) 78.41± 17.59 (88.3) 115.60± 5.23 (7.8) 151.80± 7.25 (3.9)
Alkaline phosphatase (ALP) (mg/dl) 245.54± 106.7 (98.4) N/A 487.00± 7.07 (1.6)
Gamma glutamyl transpeptidase (GGT) (mg/dl) 12.09± 3.36 (92.2) N/A 31.30± 8.43 (7.8)
Alanine aminotransferase (ALT) (mg/dl) 16.54± 8.28 (95.8) N/A 62.33± 16.58 (4.2)
Texas
Total cholesterol (mg/dl)∗
Triacylglycerides (mg/dl)
142.52± 16.03 (68.1)
93.83± 29.15 (66.7)
180.28± 8.40 (27.8)
167.29± 15.60 (21.5)
208± 9.44 (4.1)
253.76± 53.16 (11.8)
Cholesterol-HDL ratio 3.32± 0.73 (93.1) N/A 6.08± 1.43 (6.9)
High-density lipoprotein (HDL) (mg/dl)∗∗ 49.74± 9.98 (66.0) 42.89± 9.75 (21.5) 35.00± 3.40 (11.8)4
Low-density lipoprotein (LDL) (mg/dl) 79.13± 17.19 (91.0) 116.33± 5.31 (8.3) 158.00± 0.00 (0.7)
Alkaline phosphatase (ALP) (mg/dl) 225.54± 87.82 (100.0) N/A 0
Gamma glutamyl transpeptidase (GGT) (mg/dl) 14.18± 4.24 (89.6) N/A 27.87± 5.73 (10.4)
Alanine aminotransferase (ALT) (mg/dl) 15.80± 6.65 (92.4) N/A 56.64± 12.38 (7.6)
1Normal values: total cholesterol < 170mg/dl; LDL < 110mg/dl; HDL cholesterol ratio < 45mg/dl; ALP 91–476 UL for males and 104–471 UL for females; GGT
8–32 UL for males and 7–18 UL for females; ALT 8–50 UL for males and 7–33 UL for females. 2Borderline values: total cholesterol 170–199mg/dl; HDL 45–
40mg/dl; LDL 110–129mg/dl; HDL cholesterol ratio 35–45mg/dl. No borderline values for ALP, GGT, and ALT available. 3High/low values: total
cholesterol ≥ 200mg/dl; HDL ≤ 35mg/dl; LDL ≥ 130mg/dl; HDL cholesterol ratio ≤ 35mg/dl; ALP, GGT, and ALT below or above normal values for males
and females. N/A: not applicable. ∗p < 0 05 between males (p = 0 014); ∗∗p < 0 05 between sites (p = 0 012). 4Low nonhigh values for high-density lipoproteins.
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consumption, and/or high transferrin saturation [9]. No ado-
lescent reported to have alcohol consumption or had any
disease, and it is not likely that many adolescents would have
had hepatitis soon after we took the blood samples. There is
evidence suggesting that an increase in ALT is associated
with a higher risk for T2DM; however, the studies were per-
formed in high-risk populations and in adults [9, 14, 17– 19,
21, 37, 38]. It seems possible that puberty along with the
rapid growth, hormonal changes, and the physiological insu-
lin resistance characteristic of this period of life will inﬂuence
liver biomarkers [39].
There is evidence that Mexican-American and Mexican
adolescents with newly diagnosed T2DM are more likely to
have ALT values above the upper normal limit and have
higher risk to develop higher ALT concentrations compared
with non-Hispanics (whites and American-Americans).
However, mean ALT concentrations in our study were lower
compared with the Hispanics’ values reported before [40].
Although our adolescents were at risk and not diabetic, their
ALT concentrations show evidence that there is a window of
opportunity for timely preventive actions.
GGT may be a better marker than ALT for the prognosis
of T2DM, even within normal ranges, that has been recently
proposed [9, 20]. In our study, we found higher GGT concen-
trations in high-risk Mexican-American adolescents in Texas
compared with high-risk Mexican adolescents in Toluca. To
our knowledge, ethnicity do not aﬀect GGT concentrations
and there is evidence of the association between high GGT
values and impaired glucose tolerance particularly in
Mexican population. A longitudinal study by Nannipieri
et al. [40] in Mexican adults to test the hypothesis that
enzymes conventionally associated with liver dysfunction
may predict diabetes found that mild elevations in liver
enzymes are associated with features of the metabolic
syndrome; however, only raised GGT was an independent
predictor of deterioration of glucose tolerance to impaired
glucose tolerance or diabetes. Therefore, given our ﬁndings,
we can think there is an increased risk for T2DM among
high-risk Mexican-American adolescents in Texas that is
consistent with the high prevalence of T2DM there. Further-
more, the higher levels of GGT observed in males compared
with females might be reﬂected in an increased risk for
T2DM among Mexican adolescents in Toluca too.
Similar to high GGT serum concentrations, high ferri-
tin concentrations have been found to be associated with
insulin resistance, as serum ferritin is a downstream
eﬀector of GGT. A combined determination of GGT and
ferritin might lead to better predictions in patients with
insulin resistance [41]; nonetheless, we did not include
ferritin assessment in the study.
Regarding ALP, there is ALP activity in all tissues,
particularly liver, bile duct, kidney, bones, intestinal
mucosa, and placenta. In our study, we found serum
ALP diﬀerences by sex and by risk status. However, serum
ALP values were not fractionated, and therefore we cannot
assure values reﬂect true liver ALP. High ALP values in
children and adolescents can be reﬂective of bone growth
[42]; both high- and low-risk adolescents should be
experiencing bone growth at some degree. Therefore,
high-risk adolescents are demonstrating metabolic changes
reﬂected in their liver function that are known to signal
the development of T2DM.
Our results highlight the need for further understanding
the underpinnings of the onset of risk factors for T2DM
among adolescent females and males. A better understanding
of the cross-cultural diﬀerences in the developmental trajec-
tory of T2DM and the pathophysiology are also needed to
conﬁrm and understand the predictive value of liver enzymes
in relation to T2DM in adolescents.
We observed signiﬁcant sex diﬀerences in all three liver
enzyme serum concentrations both in Toluca and in Texas.
After controlling for sex and for BMI, our results were simi-
lar; only LDL concentrations were diﬀerent by risk status
when controlling for BMI. Diﬀerences between males and
females have been previously reported in adolescents and
are thought to be caused by hormonal diﬀerences [42]. As
our study was done with adolescents, it is possible that we
had hormonal diﬀerences by a sex eﬀect and by a puberty
eﬀect, so that controlling for sex accounted for the diﬀerences
in body fat distribution reﬂected in the BMI of females. We
did ask our participants to compare their development to
most girls/boys of similar age and found no diﬀerences
between Mexican-American and Mexican adolescents, both
males and females.
The prevalence of diabetes is extremely high among
Mexican-American adolescents in Texas compared with
Mexican adolescents in Toluca (28% and 0.7%, resp.).
Even when our study was done because of its feasibility
in Texas and Toluca, given the obesity epidemic in Mexico
and in the US, it seems reasonable that environmental factors
are activating the development of T2DM not only among
Mexican-American adolescents but also among Mexican
adolescents. As this was a cross-sectional study, we are
unable to ascertain that adolescents with high concentrations
of liver enzymes will develop diabetes nor when they will
develop it. However, our results suggest liver metabolic dys-
function or abnormalities at an early age, both in girls and
boys, probably characterized by liver fat, early liver insulin
resistance, and inﬂammation.
The high presence of risk factors among Mexican
adolescents has not reached public awareness, perhaps
because the prevalence of T2DM is still low. Therefore,
some of them may develop T2DM or other metabolic
condition like cardiovascular disease or hypertension,
especially those classiﬁed as high-risk individuals, and
live with its comorbidities and its consequences due to
inadequate prevention eﬀorts.
An important limitation to our study was the diﬀerence
in recruitment between locations. In Toluca, participants
were recruited from public elementary and middle schools,
and in Texas, participants were recruited from clinics and
community events. Participants in Texas may have been
unhealthier since they were recruited from clinics, and par-
ents may have been more likely to contact study personnel
if they felt their child was at high risk. Thus, the Texas sample
is not representative of the general population. Future studies
should try to broaden recruitment to improve comparisons
and generalizability of the results.
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5. Conclusions
A great majority of 10- to 14-year-old adolescent females and
males in Toluca and in Texas have multiple risk factors for
T2DM that may lead to metabolic complications. Most of
them can be prevented and reverted to avoid the onset of
T2DM.We found gender diﬀerences and diﬀerences between
high- and low-risk adolescents in GGT, ALP, and ALT
concentrations both in Toluca and in Texas.
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